REG - Hikma Pharmaceutical - Directorate Change

Hikma PharmaceuticalsAnnouncement

13/10/2022 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221013:nRSM8383Ca&default-theme=true

RNS Number : 8383C  Hikma Pharmaceuticals Plc  13 October 2022

Hikma appoints Deneen Vojta, M.D. as a Director

 

 

London, 13 October 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
(Hikma) announces the appointment of Deneen Vojta, M.D. as an independent
Non-Executive Director, effective 1 November 2022.

 

Commenting on the appointment, Said Darwazah, Executive Chairman and CEO said
'I am delighted to welcome Deneen to the Hikma Board, 'Deneen is a seasoned
healthcare executive and medical professional with extensive experience
working in large, international, high growth organisations across the entire
spectrum of the healthcare system. She brings to the Board experience as both
an entrepreneur and a strategic leader in the healthcare industry.'

 

Deneen is President of Health Solutions and Innovation at Turning Point
Healthcare Solutions, a provider of specialty case management services and
technologies. Prior to this, she was Executive Vice President for Research and
Development at UnitedHealth Group (UHG), where she was responsible for
building new businesses and creating innovative payment and delivery system
frameworks. She was also the Founder and CEO of MYnetico, a digital weight
management platform acquired by UHG in 2006. Earlier, she served as Chief
Medical Officer of ARIA Health Care System and Health Partners of
Philadelphia.

 

Deneen is currently a Non-Executive Director of Sensei Biotherapeutics, Workit
Health and Children's Minnesota.

 

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Hussein Arkhagha, Chief Counsel and Company Secretary
        +44 (0)20 7399 2760

Susan Ringdal, EVP Strategic Planning and Global Affairs
                        +44 (0)20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPGBUUUPPGWW